Skip to main content
Signal8
Luo Ying profile photo

Ying Luo

CIK: 0001959160

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GYRE THERAPEUTICS, INC. logo
GYRE

GYRE THERAPEUTICS, INC.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • GYRE THERAPEUTICS, INC. logo
    GYRE

    GYRE THERAPEUTICS, INC.

    Jun 8, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    120K shares-
  • GYRE THERAPEUTICS, INC. logo
    GYRE

    GYRE THERAPEUTICS, INC.

    May 6, 2026
    Sale(S)
    Indirect
    10.1K shares at avg. $8.04$81K
  • GYRE THERAPEUTICS, INC. logo
    GYRE

    GYRE THERAPEUTICS, INC.

    May 5, 2026
    Sale(S)
    Indirect
    179 shares at avg. $8.01$1K

1-3 of 3

About Luo Ying

Luo Ying (SEC CIK 0001959160) files insider reports with the SEC as Chief Executive Officer of GYRE THERAPEUTICS, INC. (GYRE).

Signal8 holds 3 ownership filings by Luo Ying (1 Form 3, 2 Form 4), filed between May 7, 2026 and Jun 10, 2026. Those filings report 3 transactions, from May 5, 2026 to Jun 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Luo Ying's filings is in SAN DIEGO, CA.

Recent filings by Luo Ying

  • Jun 8, 2026: Grant or award of GYRE derivative securities (Form 4, code A).
  • May 6, 2026: Open-market sale of GYRE shares (Form 4, code S).
  • May 5, 2026: Open-market sale of GYRE shares (Form 4, code S).

Other insiders filing for GYRE THERAPEUTICS, INC. (GYRE)

How to read Form 4 transaction codes